Israeli pharmaceutical giant Teva is set to donate millions of doses of a malaria drug to US hospitals in a bid to meet the demand to investigate the medicine as a potential treatment candidate for COVID-19. The latter is the disease caused by the novel coronavirus known as 2019-nCoV and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Teva said in a statement that it will ship six million tablets of hydroxychloroquine sulfate, an FDA-approved drug for malaria, lupus erythematosus and rheumatoid arthritis, to hospitals across the country by March 31, and more than 10 million by next month.
Hydroxychloroquine sulfate is not yet FDA-approved for the treatment of COVID-19, but both the drug and chloroquine phosphate, a related antiviral medication, are currently under investigation for efficacy against the coronavirus and have been requested by US government officials to be made available for use immediately.
Read More →